- Home
- CELU vs LTRN Comparison
CELU vs LTRN Comparison
Compare CELU & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- LTRN
- Stock Information
- Founded
- CELU 2016
- LTRN 2013
- Country
- CELU United States
- LTRN United States
- Employees
- CELU N/A
- LTRN N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- CELU Health Care
- LTRN Health Care
- Exchange
- CELU Nasdaq
- LTRN Nasdaq
- Market Cap
- CELU 42.2M
- LTRN 46.7M
- IPO Year
- CELU N/A
- LTRN 2020
- Fundamental
- Price
- CELU $1.73
- LTRN $3.32
- Analyst Decision
- CELU
- LTRN Hold
- Analyst Count
- CELU 0
- LTRN 1
- Target Price
- CELU N/A
- LTRN N/A
- AVG Volume (30 Days)
- CELU 162.2K
- LTRN 27.6K
- Earning Date
- CELU 12-06-2024
- LTRN 03-27-2025
- Dividend Yield
- CELU N/A
- LTRN N/A
- EPS Growth
- CELU N/A
- LTRN N/A
- EPS
- CELU N/A
- LTRN N/A
- Revenue
- CELU $48,200,000.00
- LTRN N/A
- Revenue This Year
- CELU N/A
- LTRN N/A
- Revenue Next Year
- CELU $233.89
- LTRN N/A
- P/E Ratio
- CELU N/A
- LTRN N/A
- Revenue Growth
- CELU 225.94
- LTRN N/A
- 52 Week Low
- CELU $1.00
- LTRN $2.79
- 52 Week High
- CELU $5.69
- LTRN $9.96
- Technical
- Relative Strength Index (RSI)
- CELU 48.24
- LTRN 36.70
- Support Level
- CELU $1.64
- LTRN $3.40
- Resistance Level
- CELU $2.40
- LTRN $4.00
- Average True Range (ATR)
- CELU 0.20
- LTRN 0.23
- MACD
- CELU 0.03
- LTRN -0.01
- Stochastic Oscillator
- CELU 26.26
- LTRN 3.28
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.